Emerging serine-threonine kinase inhibitors for treating ovarian cancer

@article{Maoz2019EmergingSK,
  title={Emerging serine-threonine kinase inhibitors for treating ovarian cancer},
  author={Asaf Maoz and Marcia A Ciccone and S. Matsuzaki and R. Coleman and K. Matsuo},
  journal={Expert Opinion on Emerging Drugs},
  year={2019},
  volume={24},
  pages={239 - 253}
}
ABSTRACT Introduction: Ovarian cancer is the leading cause of gynecologic cancer death, owing to high rates of incurable, recurrent disease after initial treatment. Serine threonine kinases (STKs) have been proposed as potential therapeutic targets in ovarian cancer because of their role in the initiation and progression of cancers. Experience in non-ovarian cancers suggests that STK inhibitors are active against tumors with specific molecular alterations. Areas covered: This review discusses… Expand
Ovarian Cancer: Molecular Classification and Targeted Therapy
Expression and molecular profiles of the AlkB family in ovarian serous carcinoma

References

SHOWING 1-10 OF 132 REFERENCES
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
Phase III trials in ovarian cancer: The evolving landscape of front line therapy.
Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors
Cyclin E as a potential therapeutic target in high grade serous ovarian cancer.
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition
...
1
2
3
4
5
...